The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Anti-BCMA lipid-based nanoparticle therapeutic strategy for patients with multiple myeloma
Zahraa Al-Ahmady, BSc, MSc, PhD, Nottingham Trent University, Nottingham, UK, discusses the feasibility and advantages of a novel anti-BCMA lipid-based nanoparticle therapeutic strategy designed to improve the tolerance and availability of BCMA-directed therapies for patients with multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
